You have 9 free searches left this month | for more free features.

β-thalassaemia

Showing 1 - 25 of 1,062

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Transfusion Dependent Beta-Thalassaemia Trial in Nanning (ET-01)

Recruiting
  • Transfusion Dependent Beta-Thalassaemia
  • ET-01
  • Nanning, Guangxi, China
    PLA 923 Hospital
Mar 2, 2023

Transfusion Dependent Beta-Thalassaemia Trial in Guangzhou, Shenzhen, Tianjin (ET-01)

Active, not recruiting
  • Transfusion Dependent Beta-Thalassaemia
  • ET-01
  • Guangzhou, Guangdong, China
  • +3 more
May 9, 2022

Transfusion Dependent Beta-Thalassaemia Trial in Tianjin (ET-01)

Active, not recruiting
  • Transfusion Dependent Beta-Thalassaemia
  • ET-01
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Dec 9, 2021

Sickle Cell Disease, Sickle Cell Trait, Beta-Thalassemia Trial (High performance liquid chromatography, Automated sickling test,

Not yet recruiting
  • Sickle Cell Disease
  • +4 more
  • High performance liquid chromatography
  • +5 more
  • (no location specified)
Aug 17, 2022

Thalassemia Major, Transfusion-dependent Anemia Trial in Guangzhou (Luspatercept Injectable Product)

Recruiting
  • Thalassemia Major
  • Transfusion-dependent Anemia
  • Luspatercept Injectable Product
  • Guangzhou, Guangdong, China
    The second affiliated hospital of Sun Yat-sen University
Jul 15, 2022

ß-thalassemia Trial in Shenzhen (ß-globin restored autologous hematopoietic stem cells)

Recruiting
  • β-thalassemia
  • β-globin restored autologous hematopoietic stem cells
  • Shenzhen, Guangdong, China
    Shenzhen Children's Hospital
Feb 24, 2023

Transfusion-dependent ß-thalassemia Patients, Cardiac Iron Overload Trial in Athens, Patras (Deferasirox, Deferoxamine (DFO))

Terminated
  • Transfusion-dependent β-thalassemia Patients
  • Cardiac Iron Overload
  • Athens, GR, Greece
  • +3 more
Oct 21, 2019

ß-thalassemia Trial in Shenzhen (ß-globin restored autologous hematopoietic stem cells)

Recruiting
  • β-thalassemia
  • β-globin restored autologous hematopoietic stem cells
  • Shenzhen, Guangdong, China
    Shenzhen University General Hospital
May 8, 2023

The Prevelence of HBB c.93-21 G-A in ß Thalassemia Patients

Recruiting
  • Beta-Thalassemia
  • ARMS PCR
  • Assiut, Egypt
    Faculty of Medicine Assiut University
Jan 30, 2023

Transfusion-dependent Beta-Thalassemia Trial in Tianjin (KL003 cell injection Drug Product)

Not yet recruiting
  • Transfusion-dependent Beta-Thalassemia
  • KL003 cell injection Drug Product
  • Tianjin, Tianjin, China
    Regenerative Medicine Center
May 8, 2023

The Prevelence of IVS 1-6 [HBB:c.92 +6 T-C] Gene Mutation in

Not yet recruiting
  • Beta-Thalassemia
  • ARMS
  • (no location specified)
May 10, 2022

Transfusion-dependent Beta-Thalassemia Trial in Peshawar (Thalidomide)

Completed
  • Transfusion-dependent Beta-Thalassemia
  • Peshawar, Khyber Pakhtunkhwa, Pakistan
    Blood Care Clinic
Nov 19, 2023

Beta Thalassemia Intermedia Trial in Worldwide (IONIS TMPRSS6-LRx)

Active, not recruiting
  • Beta Thalassemia Intermedia
  • Camperdown, New South Wales, Australia
  • +18 more
Sep 23, 2022

Beta Thalassemia Major, Beta Thalassemia Intermedia Trial in Worldwide (SOTATERCEPT (ACE-011))

Completed
  • Beta Thalassemia Major
  • Beta Thalassemia Intermedia
  • SOTATERCEPT (ACE-011)
  • Créteil, France
  • +14 more
Aug 18, 2022

Transfusion Dependent Beta-Thalassemia Trial in Nanning (GMCN-508B (LentiRed))

Recruiting
  • Transfusion Dependent Beta-Thalassemia
  • GMCN-508B (LentiRed)
  • Nanning, Guangxi, China
    The affiliated hospital of guangxi medical university
Feb 28, 2023

Genetic and Haematological Modifiers of SCD Severity in Kaduna

Not yet recruiting
  • Sickle Cell Disease
    • (no location specified)
    Apr 27, 2023

    Beta-Thalassemia Trial in Bulgaria, Israel, United States (VIT-2763 60 mg QD, VIT-2763 60 mg BID, VIT-2763 120 mg BID)

    Withdrawn
    • Beta-Thalassemia
    • VIT-2763 60 mg QD
    • +3 more
    • Whittier, California
    • +6 more
    Nov 7, 2022

    Beta-Thalassemia Trial in Ferrara, Firenze, Pisa (Sirolimus 0.5 mg)

    Recruiting
    • Beta-Thalassemia
    • Sirolimus 0.5 mg
    • Ferrara, FE, Italy
    • +3 more
    Nov 11, 2021

    Thalassemia, Iron Overload Trial in Nanning (CN128 Tablets)

    Recruiting
    • Thalassemia
    • Iron Overload
    • CN128 Tablets
    • Nanning, Guangxi, China
      The First Affiliated Hospital Of Guangxi Medical University
    Aug 3, 2022

    Non-transfusion-dependent Thalassemia, Low Risk Myelodysplastic Syndrome, Very-Low Risk Myelodysplastic Syndrome Trial in

    Recruiting
    • Non-transfusion-dependent Thalassemia
    • +2 more
    • Düsseldorf, Germany
    • +19 more
    Mar 18, 2022

    Thalassemia, Beta, Thalassemia Major Trial in Tianjin (VGB-Ex01)

    Not yet recruiting
    • Thalassemia, Beta
    • Thalassemia Major
    • VGB-Ex01
    • Tianjin, Tianjin, China
      Regenerative Medicine Center
    Sep 11, 2023

    Pumilio1 Expression, Sickle Cell Anemia, ß-thalassemia

    Not yet recruiting
    • Sickle Cell Disease, Beta Thalassemia Intermedia
    • RNA Binding Protein Pumilio1 (PUM1) Expression by reverse transcriptase quantatative PCR
    • (no location specified)
    May 30, 2023

    Bioavailability Trial in Stuttgart (Control beta-carotene supplement plus Placebo, Control beta-carotene supplement plus iron

    Completed
    • Bioavailability
    • iron and zinc suphate supplements
    • Stuttgart, Baden-Württemberg, Germany
      University of Hohenheim
    Apr 28, 2023

    ß-thalassemia Trial in Shanghai (BD211)

    Not yet recruiting
    • β-thalassemia
    • BD211
    • Shanghai, China
      Shanghai Ruijin Hospital
    Mar 16, 2023

    ß-thalassemia Trial (BD211)

    Not yet recruiting
    • β-thalassemia
    • BD211
    • (no location specified)
    Mar 15, 2023